Algert Global LLC Grows Stake in Septerna, Inc. $SEPN

Key Points

• Algert Global increased its Septerna stake by 1,789.6% in the second quarter, holding 397,487 shares valued at approximately $13.3 million. Other major institutions, including Goldman Sachs, BlackRock, and Vanguard, also expanded or initiated positions.
• Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and an average price target of $52.44; recent targets range as high as $60.
• Septerna beat quarterly expectations, reporting a loss of $0.29 per share versus the estimated $0.43 loss and revenue of $26.75 million versus the $19.22 million consensus. However, insiders sold 61,030 shares worth about $2.33 million during the latest quarter.

Algert Global LLC lifted its position in Septerna, Inc. (NASDAQ:SEPN - Free Report) by 1,789.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 397,487 shares of the company's stock after purchasing an additional 376,452 shares during the quarter. Algert Global LLC owned about 0.85% of Septerna worth $13,312,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. TRV GP V LLC bought a new position in shares of Septerna in the second quarter worth approximately $208,160,143,000. TRV GP VI LLC purchased a new position in Septerna in the 2nd quarter worth approximately $141,048,460,000. Goldman Sachs Group Inc. grew its stake in Septerna by 86.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company's stock worth $75,698,000 after buying an additional 1,260,409 shares in the last quarter. BlackRock Inc. bought a new position in shares of Septerna in the 2nd quarter worth $64,706,000. Finally, Vanguard Group Inc. raised its position in shares of Septerna by 7.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,518,757 shares of the company's stock valued at $28,568,000 after buying an additional 104,394 shares in the last quarter.

Analyst Upgrades and Downgrades

SEPN has been the subject of several research analyst reports. JPMorgan Chase & Co. lifted their price target on Septerna from $38.00 to $48.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 19th. Wells Fargo & Company raised their price objective on Septerna from $48.00 to $50.00 and gave the company an "overweight" rating in a report on Wednesday, August 12th. HC Wainwright boosted their target price on Septerna from $40.00 to $60.00 and gave the stock a "buy" rating in a research report on Wednesday, August 12th. Raymond James Financial reaffirmed a "strong-buy" rating and issued a $49.00 target price on shares of Septerna in a research note on Tuesday, August 11th. Finally, Truist Financial lifted their price target on shares of Septerna from $35.00 to $43.00 and gave the stock a "buy" rating in a research note on Wednesday, July 1st. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $52.44.

Septerna Price Performance

Shares of SEPN stock opened at $41.30 on Wednesday. The business has a 50-day moving average of $37.06 and a 200 day moving average of $30.54. Septerna, Inc. has a 1-year low of $11.70 and a 1-year high of $51.10. The stock has a market capitalization of $1.93 billion, a PE ratio of -76.48 and a beta of 2.29.

Septerna (NASDAQ:SEPN - Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.29) EPS for the quarter, topping analysts' consensus estimates of ($0.43) by $0.14. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%.The business had revenue of $26.75 million for the quarter, compared to analysts' expectations of $19.22 million. Analysts anticipate that Septerna, Inc. will post -1.41 EPS for the current year.

Insider Buying and Selling at Septerna

In other Septerna news, SVP Daniel D. Long sold 3,334 shares of the firm's stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $34.47, for a total value of $114,922.98. Following the sale, the senior vice president owned 96,412 shares of the company's stock, valued at $3,323,321.64. This trade represents a 3.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Samira Shaikhly sold 2,178 shares of the firm's stock in a transaction on Monday, June 29th. The stock was sold at an average price of $35.18, for a total transaction of $76,622.04. Following the completion of the sale, the insider directly owned 793 shares in the company, valued at approximately $27,897.74. This trade represents a 73.31% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 61,030 shares of company stock valued at $2,329,666 in the last quarter. Company insiders own 5.80% of the company's stock.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.

Want to see what other hedge funds are holding SEPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Septerna, Inc. (NASDAQ:SEPN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source